• MM is treated with cyclophosphamide plus steroid with PI or IMID or anti-CD38.
• MM therapy combinations increase thrombotic risk.
• MM therapy can induce thrombocytopenia thereby increasing bleeding risk.
• Detailed mechanisms of the prothrombotic effects of MM treatment are unclear.
• Antiplatelet and anticoagulant drugs in combination treatments require further evaluation.